Tenaya’s interim MyClimb data suggest 93% of children with MYBPC3-associated HCM have the nonobstructive form with no approved therapies today, highlighting an urgent need for disease-modifying options and better risk stratification. ✨ What’s new 🧬 Genetics that shape outcomes 📈 Biomarker signal: LVMI 🧒 Clinical gap in pediatrics 🧪 Pipeline context: TN‑201 gene therapy ❓ […]
